Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemiaOla A. Elgamal(The Ohio State University), John C. Byrd(The Ohio State University)Journal of Hematology & OncologyJanuary 28, 202010.1186/s13045-019-0821-7Cited by 20SaveCiteExport RISWatch citationsRelated PapersBruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765|Blood|2011|791CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody|Blood|2009|128